S&P 500   4,507.13 (-1.53%)
DOW   34,347.71 (-0.84%)
QQQ   380.68 (-2.37%)
AAPL   160.52 (-1.98%)
MSFT   320.59 (-2.70%)
FB   304.71 (-1.83%)
GOOGL   2,821.69 (-1.32%)
AMZN   3,360.89 (-2.22%)
TSLA   1,016.02 (-6.32%)
NVDA   304.25 (-5.29%)
BABA   112.58 (-7.72%)
NIO   32.03 (-11.52%)
CGC   10.00 (-3.47%)
AMD   142.30 (-5.56%)
GE   92.22 (-3.16%)
MU   81.10 (-2.15%)
T   23.43 (+1.65%)
F   19.05 (-4.13%)
DIS   144.93 (-1.54%)
PFE   54.21 (+2.21%)
AMC   26.12 (-13.74%)
ACB   5.79 (-5.70%)
BA   196.38 (-2.96%)
S&P 500   4,507.13 (-1.53%)
DOW   34,347.71 (-0.84%)
QQQ   380.68 (-2.37%)
AAPL   160.52 (-1.98%)
MSFT   320.59 (-2.70%)
FB   304.71 (-1.83%)
GOOGL   2,821.69 (-1.32%)
AMZN   3,360.89 (-2.22%)
TSLA   1,016.02 (-6.32%)
NVDA   304.25 (-5.29%)
BABA   112.58 (-7.72%)
NIO   32.03 (-11.52%)
CGC   10.00 (-3.47%)
AMD   142.30 (-5.56%)
GE   92.22 (-3.16%)
MU   81.10 (-2.15%)
T   23.43 (+1.65%)
F   19.05 (-4.13%)
DIS   144.93 (-1.54%)
PFE   54.21 (+2.21%)
AMC   26.12 (-13.74%)
ACB   5.79 (-5.70%)
BA   196.38 (-2.96%)
S&P 500   4,507.13 (-1.53%)
DOW   34,347.71 (-0.84%)
QQQ   380.68 (-2.37%)
AAPL   160.52 (-1.98%)
MSFT   320.59 (-2.70%)
FB   304.71 (-1.83%)
GOOGL   2,821.69 (-1.32%)
AMZN   3,360.89 (-2.22%)
TSLA   1,016.02 (-6.32%)
NVDA   304.25 (-5.29%)
BABA   112.58 (-7.72%)
NIO   32.03 (-11.52%)
CGC   10.00 (-3.47%)
AMD   142.30 (-5.56%)
GE   92.22 (-3.16%)
MU   81.10 (-2.15%)
T   23.43 (+1.65%)
F   19.05 (-4.13%)
DIS   144.93 (-1.54%)
PFE   54.21 (+2.21%)
AMC   26.12 (-13.74%)
ACB   5.79 (-5.70%)
BA   196.38 (-2.96%)
S&P 500   4,507.13 (-1.53%)
DOW   34,347.71 (-0.84%)
QQQ   380.68 (-2.37%)
AAPL   160.52 (-1.98%)
MSFT   320.59 (-2.70%)
FB   304.71 (-1.83%)
GOOGL   2,821.69 (-1.32%)
AMZN   3,360.89 (-2.22%)
TSLA   1,016.02 (-6.32%)
NVDA   304.25 (-5.29%)
BABA   112.58 (-7.72%)
NIO   32.03 (-11.52%)
CGC   10.00 (-3.47%)
AMD   142.30 (-5.56%)
GE   92.22 (-3.16%)
MU   81.10 (-2.15%)
T   23.43 (+1.65%)
F   19.05 (-4.13%)
DIS   144.93 (-1.54%)
PFE   54.21 (+2.21%)
AMC   26.12 (-13.74%)
ACB   5.79 (-5.70%)
BA   196.38 (-2.96%)
ASX:EMD

Emyria Stock Forecast, Price & News

Add
Compare
Today's Range
N/A
50-Day Range
N/A
52-Week Range
N/A
Volume
471,333 shs
Average Volume
N/A
Market Capitalization
N/A
P/E Ratio
N/A
Dividend Yield
N/A
Beta
N/A

Receive EMD News and Ratings via Email

Sign-up to receive the latest news and ratings for Emyria and its competitors with MarketBeat's FREE daily newsletter.


About Emyria

Emyria Limited, a healthcare technology and services company, operates a network of specialist medical clinics. Its medical clinics offer treatments, such as cannabinoid-based medicines. As of July 31, 2020, the company operated four patient-focused medical clinics. It has a partnership agreement with Mind Medicine Australia to co-develop a gold-standard and data-driven clinical model for the safe provision of psychedelic-assisted therapies in Australia; and a collaboration agreement with Cann Group Limited to register CBD product as a schedule 3 medicine that would result in an over-the-counter, pharmacist-only CBD medicine. The company was formerly known as Emerald Clinics Limited and changed its name to Emyria Limited in September 2020. Emyria Limited was founded in 2018 and is headquartered in Leederville, Australia.

Headlines

Executive Chairman Stewart Washer Just Bought 1.6% More Shares In Emyria Limited (ASX:EMD)
February 12, 2021 |  finance.yahoo.com
See More Headlines

Industry, Sector and Symbol

Stock Exchange
ASX
Industry
Health Information Services
Sub-Industry
N/A
Sector
Medical
Current Symbol
ASX:EMD
Previous Symbol
CUSIP
N/A
CIK
N/A
Web
www.emeraldclinics.com.au
Phone
61 8 6559 2800
Fax
N/A
Employees
N/A
Year Founded
N/A

Sales & Book Value

Annual Sales
$1.98 million
Price / Sales
0.00
Cash Flow
N/A
Price / Cash Flow
6.67
Book Value
A$0.03 per share
Price / Book
N/A

Profitability

EPS (Most Recent Fiscal Year)
N/A
Net Income
N/A
Net Margins
N/A
Pretax Margin
N/A
Return on Equity
N/A
Return on Assets
N/A

Debt

Debt-to-Equity Ratio
13.23
Current Ratio
6.67
Quick Ratio
6.46

Price-To-Earnings

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A

Miscellaneous

Outstanding Shares
N/A
Free Float
N/A
Market Cap
N/A
Optionable
Not Optionable

Company Calendar

Today
12/03/2021
Next Earnings (Estimated)
1/18/2022

MarketRank™

Overall MarketRank™

1.00 out of 5 stars

Analyst Opinion: 0.0Community Rank: 5.0Dividend Strength: 0.0Insider Behavior: 0.0Valuation: 0.0 5 -4 -3 -2 -1 -












Emyria (ASX:EMD) Frequently Asked Questions

When is Emyria's next earnings date?

Emyria is scheduled to release its next quarterly earnings announcement on Tuesday, January 18th 2022.
View our earnings forecast for Emyria.

Who are Emyria's key executives?

Emyria's management team includes the following people:
  • Dr. Stewart James Washer B.Sc., BSc (Hons), Ph.D., Exec. Chairman (Age 51, Pay $259.94k)
  • Dr. Michael Winlo, MD & Director
  • Ms. Su-Mei Sain, Chief Financial Officer
  • Mr. Adam James, Chief Operating Officer
  • Dr. Alistair Vickery, Exec. Medical Director & Director
  • Mr. Simon Robertson C.A., B.Bus, M Appl. Fin, CA, Company Sec.

What is Emyria's stock symbol?

Emyria trades on the ASX under the ticker symbol "EMD."

How much money does Emyria make?

Emyria has a market capitalization of $0.00 and generates $1.98 million in revenue each year.

What is Emyria's official website?

The official website for Emyria is www.emeraldclinics.com.au.

Where are Emyria's headquarters?

Emyria is headquartered at 620 8th Ave Fl 49, New York, New York 10018-1427.

How can I contact Emyria?

Emyria's mailing address is 620 8th Ave Fl 49, New York, New York 10018-1427. The company can be reached via phone at 61 8 6559 2800.


This page was last updated on 12/3/2021 by MarketBeat.com Staff

Resources

Premium Research Tools

MarketBeat All Access subscribers can access stock screeners, the Idea Engine, data export tools, research reports, and other premium tools.

Discover All Access

Market Data and Calendars

Looking for new stock ideas? Want to see which stocks are moving? View our full suite of financial calendars and market data tables, all for free.

View Market Data

Investing Education and Resources

Receive a free world-class investing education from MarketBeat. Learn about financial terms, types of investments, trading strategies and more.

Financial Terms
Details Here

As Featured By:

MarketBeat - Stock Market News and Research Tools logo

MarketBeat empowers individual investors to make better trading decisions by providing real-time financial data and objective market analysis. Whether you’re looking for analyst ratings, corporate buybacks, dividends, earnings, economic reports, financials, insider trades, IPOs, SEC filings or stock splits, MarketBeat has the objective information you need to analyze any stock. Learn more about MarketBeat.

Twitter Facebook StockTwits

MarketBeat is accredited by the Better Business Bureau

© American Consumer News, LLC dba MarketBeat® 2010-2021. All rights reserved.
326 E 8th St #105, Sioux Falls, SD 57103 | U.S. Based Support Team at [email protected] | (844) 978-6257
MarketBeat does not provide personalized financial advice and does not issue recommendations or offers to buy stock or sell any security.

Our Accessibility Statement | Terms of Service | Do Not Sell My Information

© 2021 Market data provided is at least 10-minutes delayed and hosted by Barchart Solutions. Information is provided 'as-is' and solely for informational purposes, not for trading purposes or advice, and is delayed. To see all exchange delays and terms of use please see disclaimer. Fundamental company data provided by Zacks Investment Research.